NASDAQ$HCAT
Health Catalyst Inc · Q4 2024 earnings
Q4 2024 earnings · · After market close · Investor relations
Briefing
Health Catalyst reported strong financial performance in the fourth quarter of 2024, with significant growth in total revenue and Adjusted EBITDA.
Health Catalyst achieved strong performance in Q4 2024, with total revenue reaching $79.6 million and Adjusted EBITDA at $7.9 million, significantly exceeding the previous year's figures. The Technology segment showed notable growth, contributing to the overall positive results.
- Total revenue for Q4 2024 increased by 6% year-over-year to $79.6 million.
- Adjusted EBITDA for Q4 2024 saw a substantial increase of 485% year-over-year, reaching $7.9 million.
- The Technology segment's revenue for Q4 2024 was $51.6 million, contributing significantly to overall revenue.
- Net loss for Q4 2024 improved to -$20.7 million from -$30.3 million in the prior year.
Headline financials
Revenue & EPS history
Health Catalyst · Revenue · Quarterly
$79.6M
Revenue by segment
Health Catalyst · $73.8M total across 2 segments · Q3 2023
- Technology$46M+4.5%62.3%
- Professional Services$27.8M+14.1%37.7%
Forward guidance
Health Catalyst provided optimistic forward-looking guidance for Q1 and the full year 2025, anticipating continued revenue growth and increased Adjusted EBITDA.
Tailwinds
- Anticipated total revenue for Q1 2025 of approximately $79 million.
- Anticipated Adjusted EBITDA for Q1 2025 of approximately $4 million.
- Anticipated total revenue for full year 2025 of approximately $335 million.
- Anticipated Technology revenue for full year 2025 of approximately $220 million.
- Anticipated Adjusted EBITDA for full year 2025 of approximately $41 million, an increase from previous targets.
Headwinds
- Guidance for Adjusted EBITDA is not reconciled to net loss, the most directly comparable GAAP measure.
- Forward-looking guidance for net loss is not provided.
- Items impacting net loss, such as stock-based compensation, are not within control or reasonably forecasted.
- Future growth and financial outlook are subject to risks and uncertainties.
- Actual results may differ materially from predictions due to various factors including market conditions and regulatory changes.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2024
-3.1%
Avg return
Earnings day
-3.9%
Avg return
5 days after
-4.0%
Avg return
30 days after
41%
11 / 27 earnings
Positive
+27.3%
Q2 2024
Best reaction
-36.6%
Q2 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -9.9% | -21.7% | +4.6% | |
| Q4 2025 | -26.3% | -35.2% | -44.4% | |
| Q3 2025 | -5.6% | -20.5% | -10.2% | |
| Q1 2025 | +5.3% | +8.1% | +3.3% | |
| Q4 2024 | -11.1% | -8.5% | -7.9% | |
| Q3 2024 | +14.2% | +7.2% | +7.6% | |
| Q2 2024 | +27.3% | +7.3% | +22.9% | |
| Q1 2024 | -3.6% | +2.9% | -2.3% | |
| Q4 2023 | -14.7% | -8.9% | -14.4% | |
| Q3 2023 | +5.1% | -0.4% | +5.3% | |
| Q2 2023 | -8.0% | -5.0% | -12.4% | |
| Q1 2023 | -18.9% | -14.8% | -4.3% | |
| Q4 2022 | +7.3% | +5.8% | -14.8% | |
| Q3 2022 | +16.2% | +42.9% | +59.2% | |
| Q2 2022 | -36.6% | -34.7% | -35.9% | |
| Q1 2022 | -2.6% | +24.6% | +10.5% | |
| Q4 2021 | +1.5% | -7.1% | -3.7% | |
| Q3 2021 | -6.2% | -6.1% | -26.9% | |
| Q2 2021 | +1.5% | -2.3% | -2.8% | |
| Q1 2021 | -2.3% | -8.6% | -2.4% | |
| Q4 2020 | +0.6% | +0.1% | -2.1% | |
| Q3 2020 | -0.2% | -3.5% | +6.2% | |
| Q2 2020 | -7.2% | -10.9% | -3.4% | |
| Q1 2020 | -1.9% | -0.5% | -5.0% | |
| Q4 2019 | +1.3% | -5.8% | -20.1% | |
| Q3 2019 | +1.9% | -0.8% | -1.1% | |
| Q2 2019 | -11.5% | -7.8% | -13.1% | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro